TARGET AUDIENCE
This activity is intended for neuro-oncologists, neurosurgeons and other neuro-oncology specialists involved in the treatment of primary and metastatic central nervous system (CNS) cancers.

OVERVIEW OF ACTIVITY
Brain tumors are a diverse group of neoplasms arising from different cells within the CNS or from systemic tumors that have metastasized to the CNS. Primary brain tumors include a number of histologic types with markedly different tumor growth rates and are divided into anaplastic gliomas (anaplastic astrocytoma, anaplastic oligodendroglioma and anaplastic oligoastrocytoma) and glioblastoma multiforme (GBM) based on their histopathologic features. Despite treatment, the median survival for anaplastic oligodendroglioma is 2 to 3 years, and patients with GBM can succumb to their disease within a year of onset. Thus, clinical education regarding standard and evolving best-practice therapeutic management of these neoplasms is essential to improving patient outcomes. To bridge the gap between research and patient care, these proceedings from a case-based CME symposium during the 18th Annual Meeting of the Society for Neuro-Oncology use the perspectives of leading neuro-oncologists and neurosurgeons to apply evidence-based concepts to routine practice. By providing information on the latest research developments in the context of expert perspectives, this activity assists medical oncologists with the formulation of state-of-the-art clinical management strategies, which in turn facilitates optimal patient care.

LEARNING OBJECTIVES
• Ensure delivery of appropriate treatment for primary brain cancer through the facilitation of a multidisciplinary care plan.
• Apply the results of existing and emerging research to the evidence-based use of chemotherapy and adjuvant chemoradiation therapy for patients with Grade IV GBM.
• Communicate the benefits and risks of bevacizumab, both with and without chemotherapy, to patients with newly diagnosed or recurrent GBM.
• Describe the scientific rationale and recent research results that support ongoing investigation of novel treatments for patients with brain cancer.
• Incorporate key recent clinical trial data into treatment planning for patients with primary CNS lymphomas.
• Recall the design and eligibility criteria for ongoing clinical trials, and consider appropriate patients for study participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/SNO13/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

**Tracy Batchelor, MD, MPH**
Executive Director
Stephan E and Catherine Pappas Center for Neuro-Oncology
Massachusetts General Hospital Cancer Center
Giovanni Armenise-Harvard Professor of Neurology
Harvard Medical School
Neurologist
Massachusetts General Hospital
Boston, Massachusetts

**Consulting Agreements:** EMD Serono Inc, Merck, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc;

**Contracted Research:** AstraZeneca Pharmaceuticals LP, Millennium: The Takeda Oncology Company, Pfizer Inc.

**Nicholas Butowski, MD**
Associate Professor
Department of Neurological Surgery
Division of Neuro-Oncology
University of California, San Francisco
San Francisco, California

**Consulted Research:** Lilly; **Speakers Bureau:** Genentech BioOncology, Roche Laboratories Inc.

**Howard Colman, MD, PhD**
Director of Medical Neuro-Oncology
Associate Professor
Department of Neurosurgery
Huntsman Cancer Institute
University of Utah
Salt Lake City, Utah

**Advisory Committee:** Novocure, Roche Laboratories Inc; **Honoraria:** Merck; **Royalties:** Castle Biosciences Incorporated.

**Minesh Mehta, MD**
Professor, Radiation Oncology
University of Maryland
Baltimore, Maryland

**Board of Directors:** Pharmaclics Inc; **Consulting Agreements:** Abbott Laboratories, Bristol-Myers Squibb Company, Elekta, Genentech BioOncology, Merck, Novelos Therapeutics Inc, Novocure, Phillips HealthCare Services Ltd; **Speakers Bureau:** Merck; **Stock Ownership:** Accuray.

**Michael A Vogelbaum, MD, PhD**
Professor of Surgery (Neurosurgery)
The Robert W and Kathryn B Lamborn Chair for Neuro-Oncology
Cleveland Clinic Lerner College of Medicine
of Case Western Reserve University
Associate Director
Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center
Cleveland Clinic
Cleveland, Ohio

**Consulting Agreement:** Merck; **Data Safety Monitoring Committee:** Neuralstem Inc; **Ownership Interest:** Infuseon Therapeutics Inc.


RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Genentech BioOncology and Novocure.

Hardware/Software Requirements:
- A high-speed Internet connection
- A monitor set to 1280 x 1024 pixels or more
- Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
- Adobe Flash Player 10.2 plug-in or later
- Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio

Last review date: February 2014
Expiration date: February 2015
Tracy Batchelor, MD, MPH


Omuro AMP et al. Multicenter randomized phase II trial of methotrexate (MTX) and temozolomide (TMZ) versus MTX, procarbazine, vincristine, and cytarabine for primary CNS lymphoma (PCNSL) in the elderly: An Anocet and Goelams Intergroup study. *Proc ASCO* 2013;Abstract 2032.


Nicholas Butowski, MD


Chinot O et al. Phase III trial of bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed glioblastoma: Mature progression-free survival and preliminary overall survival results in AVAglio. SNO 2012;Abstract OT-03.


Henriksson R et al. Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). *Proc ASCO* 2013;Abstract 2005.


Saran F et al. The addition of bevacizumab (BEV) to temozolomide (TMZ) and radiation therapy (RT) in newly diagnosed glioblastoma (GBM) improves progression-free survival (PFS) without adding to RT toxicity. ASTRO 2013;Abstract 37.


Howard Colman, MD, PhD


Reardon D et al. **ReACT:** A phase II study of rindopepimut vaccine (CDX-110) plus bevacizumab in relapsed glioblastoma. SNO 2013;Abstract IT-018.

Reardon DA et al. **REACT:** A phase II study of rindopepimut (CDX-110) plus bevacizumab (BV) in relapsed glioblastoma (GB). *Proc ASCO* 2012;**Abstract TPS2103**.


Wong ET et al. Analysis of the response profile to NovoTTF-100A treatment in patients with recurrent GBM: Time to effect, response duration and transient progresses in the EF-11 phase III trial. SNO 2012;**Abstract NO-47**.

**Minesh Mehta, MD**


Furuse M et al. Bevacizumab for progressive radiation necrosis: Preliminary results and ongoing clinical trial. SNO 2012;**Abstract OT-01**.

Perry JR et al. A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (NCIC CTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677). *Proc ASCO* 2012;**Abstract TPS2104**.


**Michael A Vogelbaum, MD, PhD**


